Market news

Hinge Health's (HNGE) growth outlook is supported by "higher member participation," expansion of its

Osterweis Capital Management, an investment management firm, released its Q2 2026 investor update for its “Osterweis Opportunity Fund”. You can download a copy of the letter here. The fund returned 35.34% in the quarter, significantly outperforming the Russell 2000 Growth Index’s 25.71% gain. Robust corporate profits, AI investment, easing oil-shock concerns, strong labor markets, and […]

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

Jim Cramer put Hinge Health (HNGE) in the spotlight on a recent Mad Money lightning round, contrasting its rapid expansion with Aveanna Healthcare as investors reassess digital musculoskeletal care businesses. Hinge Health has been riding strong momentum, with the share price at $94.9 after a 36.7% 90 day share price return and a 108.3% year to date share price return. The 1 year total shareholder return of 66.8% shows how quickly sentiment has shifted in favor of the stock. Scan beyond Hinge...

A caller asked for Jim Cramer’s long-term thoughts on Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) during the lightning round of the September 14 episode of Mad Money. He replied: They have a good model. They remind me of Hinge, not exactly, but in just this kind of discreet good model will make money. And I think […]

James Budge, Chief Financial Officer, on September 10, 2026, sold 55,561 shares in Hinge Health (HNG

Expanding his fantasy stock lineup on Mad Money’s episode aired on September 8, Jim Cramer turned his focus to digital healthcare provider Hinge Health, Inc. (NYSE:HNGE) to fill an important roster spot. He said: You need a tight end. This is a hybrid offensive position. On some plays, the tight end acts like an offensive […]

Leslie maintains a $2.6 million stake after the 4% reduction.

Hinge Health Inc. (HNGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hinge Health, Inc. (NYSE:HNGE) raised its full-year 2026 revenue guidance to between $856 million and $860 million, well above consensus estimates of $822.16 million. The upbeat outlook follows a standout Q2 2026 performance where revenue jumped 53% year-over-year to $213 million. Non-GAAP operating income more than doubled to $62 million (a 29% operating margin), while […]

AI pain management mobile program provider Hinge Health stock is in a buy zone above a 93.13 pivot, soaring 95% in 2026.

With poor seasonality and bond worries weighing on stocks, the job is to protect capital and build a shopping list.

Hinge stock found support at a key level in recent weeks and is approaching multiple new buy points despite market weakness.

Hinge Health (HNGE) heads into its August 19 appearance at the 5th TestMu Conference, where Head of AI Rashi Agrawal will present, as investors weigh the stock’s recent earnings driven surge and shifting growth profile. See our latest analysis for Hinge Health. At a share price of $88.46, Hinge Health has a 1 day share price return of 0.25% and a 90 day share price return of 60.49%, while the 1 year total shareholder return is 54.54%. This suggests recent momentum has been strongest in the...

Hinge Health's stock has surged in 2026 on strong Q2 earnings and expansion into migraine and GI care, but its rich valuation leaves little room for execution missteps.

Hinge Health stock has delivered a strong year to date gain, yet the current valuation checks point to a share price that screens as expensive on traditional multiples and only a mixed overall value profile. Hinge Health is up 94.2% year to date, which puts extra focus on whether recent optimism is already reflected in the current price. The long term appeal of Hinge Health can depend on the company turning its product reach into sustained revenue growth. Any setback in scaling efficiently...

Hinge Health (NYSE: HNGE) plans to present at the 5th TestMu Conference, with the company’s Head of AI scheduled as a speaker. The appearance focuses on Hinge Health’s use of artificial intelligence in digital musculoskeletal care and broader health tech workflows. The conference slot gives the company a platform to outline its current AI approach to an audience of engineers, product leaders and potential partners. For more ideas in this corner of healthcare and AI, explore the related set...

Hinge Health, Stock Of The Day, is consolidating after an earnings-related surge.

Hinge Health's nearly 90% YTD surge is backed by 53% revenue growth, wider margins and expansion into migraine and GI care, but execution risks remain.

HNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.

On August 4, Hinge Health (NASDAQ:HNGE) delivered a quarter that beat its own guidance on nearly every line, then turned around and used the extra cash to buy its way into a brand new category. Revenue grew 53% year-over-year, margins expanded by roughly 1,000 basis points, and the company still found $105 million to acquire […]

HNGE's $105 million Cylinder deal opens a $135 billion GI care market, adding nearly 100 clients and about 2 million lives.

Investors need to pay close attention to HNGE stock based on the movements in the options market lately.

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Hinge Health (HNGE) drew investor attention on 4 August 2026 after reporting second quarter earnings, issuing updated guidance for 2026, and detailing recent share repurchases under its expanded buyback authorization. See our latest analysis for Hinge Health. At a share price of $80.79, Hinge Health has a 1-day share price return of 1.73% and a 7-day share price return of 7.56%, while the 30-day share price return is down 9.53%. Even so, the 90-day share price return of 44.22%, year to date...

Hinge Health (HNGE) has an average rating of buy and mean price target of $100.67, according to anal

Hinge Health (NYSE:HNGE) reported second-quarter 2026 revenue of $213 million, up 53% from a year earlier and above the company’s prior guidance range of $200 million to $202 million. The digital healthcare company also raised its full-year revenue and operating-income outlook, citing durable improv

Hinge Health Inc. (HNGE) delivered earnings and revenue surprises of 0.00% and +6.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?